Answers are grounded in this paper and cite their sources.
The synthesis of (−)-stipiamide ( 1 ) is reported together with the designed enynes 2 (6,7-dehydrostipiamide) and 3 that are now shown to reverse the multidrug resistance (MDR) of human breast cancer cells (MCF-7adrR). Stipiamide was assembled using a Stille coupling with ( E )-vinyl iodide 17 and ( Z )-stannyl amide 16 in 78% yield. ( E )-Vinyl iodide 17 was made using a Takai reaction and a selective dihydroxylation of the terminal olefin of nonconjugated diene 7 using the Sharpless AD-mix reagent. The precursor to 16, ( E,Z )-stannyl diene ester 13, was assembled with high selectivity in a single operation using a tandem syn- addition of tributyltin cuprate to acetylene followed by conjugate addition to ethyl propiolate. Structural variants 2 and 3 were assembled using palladium-catalyzed Sonogashira couplings with vinyl iodides 17 and 35 and acetylenes 22 and 26 in high yield at near 1:1 stoichiometry. Compound 2 was found to be far less toxic than stipiamide and performed much better as an MDR reversal agent. Compound 3 was better still due to even lower toxicity.
No takes yet. Share an insight, caveat, or question.
Andrus et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: